Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-159. (Canceled)

160. (New) A compound of formula (I), or a solvate or pharmaceutically acceptable salt thereof:



(I)

wherein, independently at each occurrence,

X is selected from $-C(R_6,R_{14})-Y-$, and $-C(R_{13})=CH-$;

Y is selected from a direct bond, O, S, and C_1-C_4alkylene;

R_{13} is selected from hydrogen, C_1-C_6alkyl, C_3-C_8cycloalkyl, aryl, and benzyl;

R_1 and R_2, when taken together with the nitrogen atom to which they are directly attached in formula (I), form a ring denoted by formula (II):



(II)

wherein the ring of formula (II) is formed from the nitrogen as shown as well as three to nine additional ring atoms independently selected from carbon, nitrogen, oxygen, and sulfur; where any two adjacent ring atoms may be joined together by single or double bonds, and where any one or more of the additional carbon ring atoms may be substituted with one or two substituents selected from hydrogen, hydroxy, C_1-C_3hydroxyalkyl, oxo, C_2-C_4acyl, C_1-C_3alkyl, C_2-C_4alkylcarboxy, C_1-C_3alkoxy, C_1-C_{20}alkanoyloxy, or may be substituted to form a spiro five- or six-membered heterocyclic ring containing one or two heteroatoms selected from oxygen and sulfur; and any two adjacent additional carbon ring atoms may be fused to a C_3-C_8carbocyclic ring, and any one or more of the additional nitrogen ring atoms may be substituted with substituents selected from hydrogen, C_1-C_6alkyl, C_2-C_4acyl, C_2-C_4hydroxyalkyl and C_3-C_8alkoxyalkyl; or

R_1 and R_2, when taken together with the nitrogen atom to which they are directly attached in formula (I), may form a bicyclic ring system selected from 3-azabicyclo[3.2.2]nonan-3-yl, 2-azabicyclo[2.2.2]octan-2-yl, 3-azabicyclo[3.1.0]hexan-3-yl, and 3-azabicyclo[3.2.0]heptan-3-yl;

R_3 and R_4 are independently attached to the cyclohexane ring shown in formula (I) at the 3-, 4-, 5- or 6- positions and are independently selected from hydrogen, hydroxy, C_1-C_6alkyl, and C_1-C_6alkoxy;

R_5, R_6 and R_{14} are independently selected from hydrogen, C_1-C_6alkyl, aryl and benzyl;

A is selected from C_5-C_{12}alkyl, a C_3-C_{13}carbocyclic ring, and ring systems selected from formulae (III), (IV), (V), (VI), (VII) and (VIII):



(III)

where R_7, R_8 and R_9 are independently selected from bromine, chlorine, fluorine, carboxy, hydrogen, hydroxy, hydroxymethyl, methanesulfonamido, nitro, sulfamyl, trifluoromethyl,

C_2-C_7alkanoyloxy, C_1-C_6alkyl, C_1-C_6alkoxy, C_2-C_7alkoxycarbonyl, C_1-C_6thioalkyl and $N(R_{15},R_{16})$ where R_{15} and R_{16} are independently selected from hydrogen, acetyl, methanesulfonyl, and C_1-C_6alkyl;



(IV)

and



(V)

where R_{10} and R_{11} are independently selected from bromine, chlorine, fluorine, carboxy, hydrogen, hydroxy, hydroxymethyl, methanesulfonamido, nitro, sulfamyl, trifluoromethyl, C_2-C_7alkanoyloxy, C_1-C_6alkyl, C_1-C_6alkoxy, C_2-C_7alkoxycarbonyl, C_1-C_6thioalkyl, and $N(R_{15},R_{16})$ where R_{15} and R_{16} are independently selected from hydrogen, acetyl, methanesulfonyl, and C_1-C_6alkyl;



(VI)

where R_{12} is selected from bromine, chlorine, fluorine, carboxy, hydrogen, hydroxy, hydroxymethyl, methanesulfonamido, nitro, sulfamyl, trifluoromethyl, C_2-C_7alkanoyloxy, C_1-C_6alkyl, C_1-C_6alkoxy, C_2-C_7alkoxycarbonyl, C_1-C_6thioalkyl, and $N(R_{15},R_{16})$ where R_{15} and R_{16} are independently selected from hydrogen, acetyl, methanesulfonyl, and C_1-C_6alkyl; and Z is selected from CH, CH_2, O, N and S, where Z may be directly bonded to "X" as shown in formula (I) when Z is CH or N, or Z may be directly bonded to R_{17} when Z is N, and R_{17} is selected from hydrogen, C_1-C_6alkyl, C_3-C_8cycloalkyl, aryl and benzyl;



(VII)



(VIII)

including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof.

161. (New) A compound according to claim 160 having formula (IX), or a solvate or pharmaceutically acceptable salt thereof:



(IX)

wherein, independently at each occurrence,

X is selected from -C(R_6,R_{14})-Y-, and -C(R_{13})=CH-;

Y is selected from a direct bond, O and S; and

R_1, R_2, R_3, R_4, R_6, R_7, R_8, R_9, R_{10}, R_{11}, R_{12}, R_{14}, A and Z are defined as in claim 160;

including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof.

162. (New) A compound of claim 160 having formula (X), or a solvate or pharmaceutically acceptable salt thereof:



(X)

wherein, independently at each occurrence,

X is selected from -C(R_6,R_{14})-Y-, and -C(R_{13})=CH-;

Y is selected from a direct bond, O, and S;

R_1, R_2, R_6 and R_{14} are defined as in claim 160;

R_3 and R_4 are independently selected from hydrogen and C_1-C_6alkoxy; and

A is selected from C_5-C_{12}alkyl, C_3-C_8cycloalkyl, and any of formulae (III), (IV), (V), and (VI) as defined in claim 160, wherein Z, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} are defined as in claim 160;

including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof.

163. (New) A compound of claim 160 having formula (XI), or a solvate or pharmaceutically acceptable salt thereof:



(XI)

wherein, independently at each occurrence,

R_1 and R_2 are defined as in claim 160;

R_3 and R_4 are independently selected from hydrogen and methoxy; and

A is selected from C_5-C_{12}alkyl, C_3-C_8cycloalkyl, and any of formulae (III), (IV), (V), and (VI) as defined in claim 160, wherein Z, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} are defined as in claim 160;

including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof.

164. (New) A compound of claim 160 having formula (XII), or a solvate or pharmaceutically acceptable salt thereof:



(XII)

wherein, independently at each occurrence,

R_1 and R_2 are defined as in claim 160;

R_3 and R_4 are independently selected from hydrogen and methoxy; and

A is selected from C_5-C_{12}alkyl, C_3-C_8cycloalkyl, and any of formulae (III), (IV), (V) and (VI) as defined in claim 160, wherein Z, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} are defined as in claim 160;

including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof.

165. (New) A compound of claim 160 having formula (XIII), or a solvate or pharmaceutically acceptable salt thereof:



(XIII)

wherein, independently at each occurrence,

X is selected from -C(R_6,R_{14})-Y- and -CH=CH-;

Y, R_1, R_2, R_6 and R_{14} are defined as in claim 160;

R_3 and R_4 are independently selected from hydrogen and methoxy; and

A is selected from C_3-C_8cycloalkyl and any of formulae (III), (IV), (V), (VI), (VII) and (VIII) as defined in claim 160, where R_8 and R_9 are defined as in claim 49, R_7, R_{10}, R_{11} and R_{12} are hydrogen, and Z is selected from O, S and N-R_{17} where R_{17} is selected from hydrogen and methyl;

including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof.

166. (New) A compound of claim 160 having formula (XIV), or a solvate or pharmaceutically acceptable salt thereof:



(XIV)

wherein, independently at each occurrence,

R_1 and R_2 are defined as in claim 160; and

A is selected from any of formulae (III), (IV), (V) and (VI) as defined in claim 160, wherein R_7, R_{10}, R_{11} and R_{12} are hydrogen, R_8 and R_9 are independently selected from hydrogen, hydroxy, fluorine, chlorine, bromine, methanesulfonamido, methanoyloxy, methoxycarbonyl, nitro, sulfamyl, thiomethyl, trifluoromethyl, methyl, ethyl, methoxy, ethoxy and NH_2; and Z is selected from O and S;

including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof.

167. (New) A compound of claim 160 having formula (XV), or a solvate or pharmaceutically acceptable salt thereof:



(XV)

wherein, independently at each occurrence,

R_1 and R_2 are defined as in claim 160; and

A is selected from any of formulae (III), (IV), (V) and (VI) as defined in claim 160, wherein R_7, R_{10}, R_{11} and R_{12} are hydrogen, R_8 and R_9 are independently selected from hydrogen, hydroxy, fluorine, chlorine, bromine, methanesulfonamido, methanoyloxy, methoxycarbonyl, nitro, sulfamyl, thiomethyl, trifluoromethyl, methyl, ethyl, methoxy, ethoxy and NH_2; and Z is selected from O and S;

including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof.

168. (New) A compound of claim 160 having formula (XVI), or a solvate or pharmaceutically acceptable salt thereof:



(XVI)

wherein, independently at each occurrence,

X is selected from *trans*-CH=CH-, $-CH_2-$ and $-CH_2-O-$;

R_1 and R_2 taken together with the nitrogen atom to which they are attached form a ring selected from pyrrolidinyl, 2-ketopyrrolidinyl, 3-ketopyrrolidinyl, 2-acetoxypyrrolidinyl, 3-acetoxypyrrolidinyl, 2-hydroxypyrrolidinyl, 3-hydroxypyrrolidinyl, thiazolidinyl, piperidinyl, 2-ketopiperidinyl, 3-ketopiperidinyl, 4-ketopiperidinyl,acetylpiperazinyl, 1,4-dioxa-7-azaspiro[4.4]non-7-yl, hexahydroazepinyl, morpholinyl, N-methylpiperazinyl and 3-azabicyclo[3.2.2]nonanyl; and

A is selected from cyclohexyl, monochlorophenyl, 2,6-dichlorophenyl, 3,4-dichlorophenyl, 2-bromophenyl, 2,4-dibromophenyl, 3-bromophenyl, 4-bromophenyl, 3,4-dimethoxyphenyl, 1-naphthyl, 2-naphthyl, 3-benzo(b)thiophenyl, 4-benzo(b)thiophenyl, (2-trifluoromethyl)phenyl, 2,4-di(trifluoromethyl)phenyl, and (4-trifluoromethyl)phenyl;

including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof.

169. (New) A compound, or mixture comprising compounds, selected from the group consisting of:

(+)-*trans*-[2-(4-morpholinyl)-1-(2-naphthenethoxy)]cyclohexane;

(-)-*trans*-[2-(4-morpholinyl)-1-(2-naphthenethoxy)]cyclohexane;

(+)-*trans*-[2-(4-morpholinyl)-1-(1-naphthenethoxy)]cyclohexane;

(-)-*trans*-[2-(4-morpholinyl)-1-(1-naphthenethoxy)]cyclohexane;

(+)-*trans*-[2-(4-morpholinyl)-1-(4-bromophenethoxy)]cyclohexane;

(-)-*trans*-[2-(4-morpholinyl)-1-(4-bromophenethoxy)]cyclohexane;

(+)-*trans*-[2-(4-morpholinyl)-1-[2-(2-naphthoxy)ethoxy)]cyclohexane;

(-)-*trans*-[2-(4-morpholinyl)-1-[2-(2-naphthoxy)ethoxy)]cyclohexane;

(+)-*trans*-[2-(4-morpholinyl)-1-[2-(4-bromophenoxy)ethoxy]]cyclohexane;

(-)-*trans*-[2-(4-morpholinyl)-1-[2-(4-bromophenoxy)ethoxy]]cyclohexane;

(+)-*trans*-[2-(4-morpholinyl)-1-(3,4-dimethoxyphenethoxy)]cyclohexane;

(-)-*trans*-[2-(4-morpholinyl)-1-(3,4-dimethoxyphenethoxy)]cyclohexane;

(+)-*trans*-[2-(1-pyrrolidinyl)-1-(1-naphthenethoxy)]cyclohexane;

(-)-*trans*-[2-(1-pyrrolidinyl)-1-(1-naphthenethoxy)]cyclohexane;

(+)-*trans*-[2-(4-morpholinyl)-1-(2-(benzo[b]thiophen-3-yl)ethoxy)]cyclohexane;

(-)-*trans*-[2-(4-morpholinyl)-1-(2-(benzo[b]thiophen-3-yl)ethoxy)]cyclohexane;

(+)-*trans*-[2-(4-morpholinyl)-1-(2-(benzo[b]thiophen-4-yl)ethoxy)]cyclohexane;

(-)-*trans*-[2-(4-morpholinyl)-1-(2-(benzo[b]thiophen-4-yl)ethoxy)]cyclohexane;

(+)-*trans*-[2-(4-morpholinyl)-1-(3-bromophenethoxy)]cyclohexane;

(-)-*trans*-[2-(4-morpholinyl)-1-(3-bromophenethoxy)]cyclohexane;

(+)-*trans*-[2-(4-morpholinyl)-1-(2-bromophenethoxy)]cyclohexane;

(-)-*trans*-[2-(4-morpholinyl)-1-(2-bromophenethoxy)]cyclohexane;

(+)-*trans*-[2-(4-morpholinyl)-1-(3-(3,4-dimethoxyphenyl)-1-propoxy)]cyclohexane;

(-)-*trans*-[2-(4-morpholinyl)-1-(3-(3,4-dimethoxyphenyl)-1-propoxy)]cyclohexane;

(1R,2R)/(1S,2S)-2-(4-morpholinyl)-1-(3,4-dichlorophenethoxy)cyclohexane;

(1R,2R)/(1S,2S)-2-(3-ketopyrrolidinyl)-1-(1-naphthenethoxy)cyclohexane;

(1R,2R)/(1S,2S)-2-(1-acetylpiperazinyl)-1-(2-naphthenethoxy)cyclohexane;

(1R,2R)/(1S,2S)-2-(3-ketopyrrolidinyl)-1-(2,6-dichlorophenethoxy)cyclohexane;

(1R,2R)/(1S,2S)-2-[1,4-dioxa-7-azaspiro[4.4]non-7-yl]-1-(1-naphthenethoxy)cyclohexane;

(1R,2S)/(1S,2R)-2-(4-morpholinyl)-1-[(2-trifluoromethyl)phenethoxy]cyclohexane;

(1R,2R)/(1S,2S)-2-(3-ketopyrrolidinyl)-1-[3-(cyclohexyl)propoxy]cyclohexane;

(1R,2R)/(1S,2S)-2-(3-acetoxypyrrolidinyl)-1-(1-naphthenethoxy)cyclohexane;

(1R,2R)/(1S,2S)-2-(3-hydroxypyrrolidinyl)-1-(2,6-dichlorophenethoxy)cyclohexane;

(1R,2R)/(1S,2S)-2-(3-ketopyrrolidinyl)-1-(2,2-diphenylethoxy)cyclohexane;

(1R,2R)/(1S,2S)-2-(3-thiazolidinyl)-1-(2,6-dichlorophenethoxy)cyclohexane; and

(1R,2S)/(1S,2R)-2-(3-ketopyrrolidinyl)-1-(1-naphthenethoxy)cyclohexane; and

including isolated enantiomeric and diastereomeric isomers thereof, and mixtures thereof; and pharmaceutically acceptable salts thereof.

170. (New) A composition comprising a compound according to any one of claims 160-169 in combination with a pharmaceutically acceptable carrier, excipient or diluent.